Galenvs Sciences
Jacques Dessureault is a seasoned executive with extensive leadership experience across various industries. Currently serving as the CEO of Pharmascience Inc. and the Chair of the Board of Directors at TATUM bioscience, Jacques Dessureault has held multiple influential roles, including Chair of the Strategic Advisory Board at Galenvs Sciences and membership in the management committee at CHU Sainte-Justine. Previously, Jacques Dessureault was Chairman of the Board at Optina Diagnostics and a Strategic Advisor at Cirque du Soleil Entertainment Group. With a background that includes roles as President and General Manager at Bausch Health Companies Inc. and V.P. at Bristol Myers Squibb, Jacques Dessureault possesses a robust educational foundation, holding degrees from McMaster University, Université Laval, University of Leicester, and UQAM.
This person is not in any teams
This person is not in any offices
Galenvs Sciences
Galenvs is a specialized precision developer & manufacturer of nanomaterials and DNA/RNA oligonucleotides for therapeutics and diagnostic applications, offering services from proof-of-concept through in-vitro validation and pilot-scale production. Why choose us? - Proven track record of delivering solutions for a variety of industries from human to environmental and animal health - Vertical integration from lead optimization, synthesis, purification, validation and pilot-scale production - Rapid turnaround from proof-of-concept to pilot-scale informed by rich data set and predictive models Our proprietary multidisciplinary technologies in functional nanomaterials and oligonucleotide synthesis deliver value for our healthcare and industry partners. We excel in tackling complex challenges and designing robust, tailored processes optimized for client product requirements.